Remove Genetics and mental health Remove Personality disorders Remove Technology
article thumbnail

The Psychiatric Pipeline in Review: Quarter 2, 2025

Psychiatric Times

Trontinemab showed significant amyloid plaque reduction in Alzheimer's, validating Brainshuttle technology and prompting a phase 3 study. MindMed initiated a phase 3 study of MM120 for major depressive disorder, with results expected in the second half of 2026. Results are expected in 2026.

article thumbnail

FDA Requires New Label Warning of Weight Loss Risk in Pediatric Patients Taking Extended-Release Stimulants for ADHD

Psychiatric Times

SHOW MORE The FDA will update ADHD medication labels, warning of weight loss risks in children under 6, urging careful monitoring by health care professionals. Health care professionals should monitor the child’s growth and development and provide necessary interventions to mitigate weight loss.” FDA Drug Safety Communication.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Presenting Our August Theme: ADHD

Psychiatric Times

Do you have practice tips to offer your fellow mental health clinicians? Goodman, MD August 1st 2025 FDA Requires New Label Warning of Weight Loss Risk in Pediatric Patients Taking Extended-Release Stimulants for ADHD Leah Kuntz August 1st 2025 ADHD With Bipolar Disorder: Genetics, Diagnosis, and New Thinking on Treatment David N.

article thumbnail

Eyes, Ears, and Emotion: Techniques to Tackle Diagnosing Bipolar Disorder

Psychiatric Times

Emerging research on RNA biomarkers, AI applications, and genetic mutations shows promise for developing new diagnostic tools for bipolar disorder. 2 With the potential benefits of developing lab-based diagnostic tools, there are unfortunately no definitive blood tests for bipolar disorder currently.

article thumbnail

PTSD In Review: Treatment Insights

Psychiatric Times

PTSD diagnosis requires nuanced understanding, as symptoms often overlap with other psychiatric disorders, complicating discernment. Genetic links between PTSD and migraines suggest shared pathways, with genes DAPK2 and TM6SF2 implicated in both disorders.

article thumbnail

ADHD Treatment Options

Psychiatric Times

Related Videos Related Content Advertisement June 17th 2025 ADHD With Bipolar Disorder: Genetics, Diagnosis, and New Thinking on Treatment David N. Newsletter Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients. Subscribe Now!

article thumbnail

Risk Factors for ADHD

Psychiatric Times

Overview of Attention Deficit/Hyperactivity Disorder EP: 2. Role of Pediatricians in Diagnosing ADHD ADHD risk factors encompass both genetic and environmental components that significantly impact child development. ADHD in Elementary School Age Child: Patient Case 1 EP: 3. ADHD Diagnosis Criteria EP: 4. Risk Factors for ADHD EP: 7.